Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...

The FDA has freed Rocket Pharmaceuticals from a clinical hold, giving the gene therapy developer permission to take flight ...

The developer of an alternative surgical approach to glaucoma has raised $42 million to bolster the commercial launch of its ...

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...

The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several indications and silver ...

The years-long legal kerfuffle between IQVIA and Veeva Systems has come to a close, with the former adversaries ...